Objective To compare outcomes of infants and children who underwent lung transplantation for genetic disorders of surfactant metabolism (SFTPB, SFTPC, ABCA3, and NKX2-1) over 2 epochs (1993-2003 and 2004-2015) at St Louis Children's Hospital.
compare pre-transplantation characteristics, mortality, and transplantation-related morbidities in infants and children who underwent lung transplantation for genetic disorders of surfactant metabolism over the past 2 decades at St Louis Children's Hospital.
Methods
For all infants (aged <1 year; n = 28) and children (aged >1 year; n = 16) who underwent bilateral lung transplantation for genetic disorders of surfactant metabolism at St Louis Children's Hospital between 1993 and 2015, we collected age at listing, respiratory support at the time of transplantation, wait time to transplantation, survival at 1 year and 5 years posttransplantation, and common transplant-related morbidities, including cytomegalovirus (CMV) infection, seizures, hypertension, renal insufficiency, bronchiolitis obliterans, and post-transplantation lymphoproliferative disorder (PTLD) ( Table II) .
We assigned hypertension based on the need for antihypertensive medication and/or documentation by a nephrologist or pulmonologist in the medical record. We assigned renal insufficiency based on available laboratory values or clinical characteristics, including elevated creatinine level for age, glomerular filtration rate, need for dialysis or renal transplantation, and/or documentation of diagnosis of chronic kidney disease by a nephrologist or pulmonologist.
A diagnosis of bronchiolitis obliterans was assigned based on the International Society of Heart and Lung Transplant's histological grading of transbronchial biopsy or autopsy 28 and/ or documentation of diagnosis by a pulmonologist. PTLD was assigned based on positron emission tomography scan or lymph node biopsy results. Growth impairment was determined based on standardized growth charts. 29 Other outcomes assessed included the need for gastrostomy tube placement, motor and 
Results

Infants
We compared clinical characteristics for infants listed (n = 35) and transplanted (n = 28) for genetic disorders of surfactant metabolism by epoch (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) ; n = 19 listed, n = 16 transplanted and 2004-2015; n = 16 listed, n = 12 transplanted) ( Table II) . Seven infants were listed but died while awaiting transplantation. Four infants and children who were listed but later inactivated were not included in the analyses (Table III) . Most infants underwent transplantation for surfactant protein B or ABCA3 deficiency. The median time to follow-up was 67 months for the infants in epoch 1 and 59 months for those in epoch 2. There was no difference in sex distribution between infants from the 2 epochs. More infants from epoch 2 were of Hispanic or Middle Eastern descent (P = .0017). The ages of the infants at listing and transplantation, time spent awaiting transplantation, and the need for mechanical ventilation at time of transplant were similar for infants between the 2 epochs. Significantly more infants received extracorporeal membrane oxygenation (ECMO) before transplantation during epoch 1 (P = .0092). The majority of infants transplanted in epoch 1 (11 of 16) received a combination of cyclosporine and azathioprine for maintenance immunosuppression, whereas most of the infants transplanted in epoch 2 (10 of 12) were treated with tacrolimus and mycophenolate mofetil. The immunosuppressive regimens of 4 infants in epoch 1 were changed from cyclosporine and azathioprine to tacrolimus and mycophenolate mofetil for declining lung function. All infants from both epochs received corticosteroids as part of their immunosuppressive regimen.
The 1-year (81% vs 83%) and 5-year (56% vs 56%) survival rates for transplanted infants were similar for the 2 epochs (Table II) , as was mortality evaluated by Kaplan-Meier analysis (Figure 1 ; available at www.jpeds.com). Deaths among infants within the first year post-transplantation were due to non-CMV infection (n = 3) and graft-related complications, including pulmonary vein stenosis (n = 1) and bronchial stenosis (n = 1). Deaths occurring after the first year were due to bronchiolitis obliterans and infection. Despite a change in primary immunosuppressive regimens between the 2 epochs, there were no differences between infants transplanted in the 2 epochs in short-term morbidities (CMV infection, seizures) or long-term morbidities (hypertension, renal insufficiency, bronchiolitis obliterans, or PTLD) ( Table II) . Most of the infants received a gastrostomy tube for nutritional supplementation, and many infants exhibited significant growth impairment, speech and motor delays, and hearing loss (Table II) .
Children
Most of the 16 children (age >1 year at transplantation) listed and transplanted for genetic disorders of surfactant metabolism had SFTPC-associated lung disease or ABCA3 deficiency (Table II) . There were no differences in sex or race/ ethnicity between children of the 2 epochs. One child receiving ECMO died while awaiting transplantation. Children transplanted during epoch 2 were older at listing (mean, 99 months vs 41 months; P = .020) and transplantation (mean, 118 months vs 45 months; P = .015). Children in epoch 2 waited longer for transplantation (mean, 16 months vs 4.2 months), but this difference was not statistically significant (P = .055). Few children were receiving mechanical ventilation at the time of transplantation. The median time to follow-up was 94 months for children in epoch 1 and 54 months for children in epoch 2.
Most of the children transplanted in epoch 1 (6 of 9) were started on cyclosporine and azathioprine for immunosuppression; however, the majority of these children (5 of 6) were subsequently transitioned to tacrolimus and mycophenolate mofetil due to declining lung function. Most of the children transplanted during epoch 2 (6 of 7) were treated with tacrolimus and mycophenolate mofetil, and only 1 child received cyclosporine and azathioprine. All children from both epochs received steroids as a part of their immunosuppressive regimen.
All children transplanted for genetic disorders of surfactant metabolism survived to 1 year after transplantation, and 5-year survival rates were similar in the 2 epochs (78% vs 80%; P = 1.0) ( Table II) , with no differences detected by KaplanMeier survival curve analysis (Figure 2 ; available at www.jpeds.com). Deaths in the children were due to bronchiolitis obliterans and non-PTLD malignancy. There were no differences on univariate analyses for short-term morbidities (CMV infection, seizures) or long-term morbidities (hypertension, renal insufficiency, bronchiolitis obliterans, PTLD) at 5 years post-transplantation in children from the 2 epochs (Table II) . Kaplan-Meier analyses revealed that more children transplanted during epoch 1 developed hypertension (P = .049) (Figure 3, A; available at www.jpeds.com), whereas more children from epoch 2 developed PTLD (P = .051) (Figure 3, B) . The incidence of bronchiolitis obliterans was similar in children from the 2 epochs (56% vs 60%; P = 1.0) ( Table II) , with no differences detected by Kaplan-Meier analysis. Most transplanted children had growth impairment and received a gastrostomy tube (Table II) . Few children in either epoch had a significant developmental delay, and none had hearing loss at the last recorded follow-up (Table II) .
Infants vs Children
To compare outcomes for infants and children transplanted for genetic disorders of surfactant metabolism, we combined data from the 2 epochs (Table IV) . There were no differences 
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Volume 184 in sex and race/ethnicity between the infants and children. Infants were more likely to be transplanted for surfactant protein B deficiency, whereas children were more likely to be transplanted for SFTPC-associated lung disease (P < .0001); both infants and children underwent transplantation for ABCA3 deficiency (Table IV) . Compared with infants, children waited longer for donor lungs (mean, 9.3 months vs 1.9 months; P = .014) ( Table IV) and were less likely to be mechanically ventilated at the time of transplantation (13% vs 89%; P ≤ .0001) ( Table IV) . One infant from epoch 1 underwent a second transplantation at 4 months after the first transplantation due to chronic graft dysfunction. There were no differences in survival at 1 or 5 years between the infants and children (Table IV and Figure 4 , A). Kaplan-Meier analysis revealed that compared with children, infants were less likely to develop bronchiolitis obliterans (P = .021) (Figure 4, B) and more likely to have motor and speech delays (79%-86% vs 13%; P < .0001) ( Table IV) and hearing loss (33% vs 0%; P = .012) ( Table IV) .
Discussion
Mortality and long-term morbidities remain considerable for infants and children who undergo lung transplantation for genetic disorders of surfactant metabolism. Despite advances in genetic diagnosis, immunosuppressive therapies, and supportive respiratory and nutritional care, 5-year mortality was similar in both infants and children for the 2 epochs. The overall 5-year survival rates of infants (56%) and children (79%) transplanted for genetic disorders of surfactant metabolism at our single center are similar to those reported for infants and children transplanted for cystic fibrosis and pulmonary vascular disease. [30] [31] [32] As observed in prior studies of infants with surfactant protein B and ABCA3 deficiency, most infants from both epochs were critically ill at the time of transplantation, requiring mechanical ventilation (including high-frequency oscillatory ventilation) or ECMO. 33, 34 However, the timing of presentation of 6 infants (range, 2 weeks to 5 months) and 5 children with ABCA3 deficiency emphasizes the variability of disease course associated with biallelic missense, splice site, and in-frame insertion/deletions in ABCA3. 35 We did not find any differences in the age of infants at listing for transplantation or the rate of death prior to transplantation between epochs 1 and 2, suggesting that increased availability of definitive diagnostic sequencing and advances in neonatal intensive care, including additional noninvasive ventilation strategies, increased availability of nitric oxide, nutritional support, and empiric medical therapies, have not significantly impacted survival to transplantation for infants with genetic disorders of surfactant metabolism. Transplanted infants were more likely than transplanted children to have motor and speech delays, likely reflecting greater pretransplantation severity of illness and the variable prognostic accuracy of neurologic evaluation in infancy. In addition, prolonged exposure to sedative medications, intermittent hypoxic episodes, suboptimal nutrition, and decreased developmental stimulation while awaiting transplantation may contribute to poor developmental outcomes in transplanted infants. Our study is limited in that not all infants and children underwent formal developmental testing, and we may not have accounted for "catch-up" development or school readiness/performance. Bronchiolitis obliterans remains a leading cause of death after the first year post-transplantation for pediatric lung transplant recipients. 30 Similar to a previous report from our institution, 36 we also found a decreased incidence of bronchiolitis obliterans among infant lung transplant recipients compared with children (P = .021) (Figure 4, B) ; however, posttransplantation mortality was similar in infants and children (Figure 4, A) and consistent with other studies. 30, 31 In addition, rates of bronchiolitis obliterans were similar in the 2 epochs for both infants and children (Table II) . A lower incidence of bronchiolitis obliterans among infant recipients may reflect immaturity of the infant immune system at time of transplantation. 36 Although more children in epoch 2 developed PTLD compared with children in epoch 1 (Figure 3, B) , the overall incidence of PTLD among infants and children in our study was similar to previous reports. 36 Records of pretransplantation Epstein-Barr virus status were incomplete, and thus this was not included in our analyses.
Prior studies from eras corresponding to epoch 1 and epoch 2 found similar rates of renal dysfunction (30%-40%) 30, 37 and suggest that renal insufficiency and hypertension (nearly 70% of patients) 30 may develop due to side effects of chronic immunosuppressive medications.
The lower rates of renal insufficiency and hypertension at 5 years post-transplantation seen in this study compared with other studies may be due to incomplete recording of diagnoses in the medical chart. Fewer children developed hypertension in epoch 2 (Figure 3, A) , possibly related to modifications to immunosuppressive regimens.
Growth impairment continues to be a major challenge for both infant and child lung transplant recipients. 37, 38 Poor nutritional status prior to transplantation independently increases post-transplantation mortality among adult recipients. 39 The majority of infants and children in our study underwent gastrostomy tube placement for nutritional supplementation and exhibited growth impairment post-transplantation. A previous study from our institution reported an average posttransplantation linear growth of 64% of predicted during the first year of follow-up for infant and child lung transplant recipients. 38 Although responses to empiric medical therapies, including corticosteroids, azithromycin, and hydroxychloroquine, have been observed in some infants and children with ABCA3 deficiency or SFTPC mutations, 17, 18, 20, 22, 32, 40 others progress to transplantation or death despite these therapies. 35, 41 Infants with biallelic loss of function (nonsense, frameshift) mutations in SFTPB and ABCA3 present with severe respiratory failure at birth and die without lung transplantation by age 1 year; 35, 42, 43 however, genotype-phenotype correlations for infants and children with SFTPC, NKX2-1, and other (missense, splice site, in-frame insertion/deletion) ABCA3 mutations are more variable and thus more difficult to predict. 35, [44] [45] [46] This variability in disease course is highlighted by the observation that 4 infants and children listed for transplantation were later inactivated due to improved or stable lung function ( Table III) . Three of these children had SFTPC mutations, and 1 child was compound heterozygous for a frameshift and an in-frame deletion in ABCA3. Less-predictable genotype-phenotype correlations and variability in disease course complicate discussions with families regarding lung transplantation. Tracheostomy and chronic ventilation in combination with empiric anti-inflammatory agents (corticosteroids, azithromycin, hydroxychloroquine, and/or azathioprine) have been suggested as alternatives to lung transplantation for infants and children with SFTPC mutations and severe, persistent respiratory failure, with some children decannulated and weaned from all respiratory support over 2-6 years. 19, 22 Along with further characterization of the natural histories of infants and children with variable genotype-phenotype correlations (SFTPC, NKX2-1, and "other" ABCA3 mutations), studies of factors (genetic and environmental) that contribute to prolonged survival without transplantation, functional studies of disease mechanisms, and randomized clinical trials of pharmacotherapeutics are needed to determine whether anecdotal responses to empiric therapies are related to disease amelioration or to the natural waxing/waning disease course of chILD. 47 Although transplantation may permit short-term survival for infants and children with otherwise lethal genetic lung disease, it is associated with chronic medical challenges and long-term morbidities. Counseling that reflects these realities likely contributes to the parental decision to not pursue lung transplantation for approximately 50% of families. 27, 34 In addition to medical complications of transplantation, families face considerable social challenges, given the need for frequent follow-up at the transplantation center in the months and years after transplantation for surveillance bronchoscopies, pulmonary function tests, and laboratory evaluations. Because genetic disorders of surfactant metabolism are rare, a multidisciplinary care delivery model including a team of physicians (lung transplant pulmonologists, neonatologists, cardiothoracic surgeons, geneticists, nephrologists, neurologists), social workers, nutritionists, physical and occupational therapists, audiologists, and families of prior transplant recipients is needed to optimize care for affected infants and children. Interdisciplinary coordination can inform families of the risks and benefits of lung transplantation, optimize pre-transplantation and post-transplantation care, support families with their decisions, and communicate genetic recurrence risk. Prospective studies such as those currently in development through the Children's Interstitial Lung Disease Research Network to characterize the natural history, develop strategies to optimize pre-transplantation health status, and devise approaches to reduce the incidence of bronchiolitis obliterans are needed to improve outcomes for infants and children with genetic disorders of surfactant metabolism. 
